For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
HOME > ARCHIVE
ARCHIVE
- BUSINESS NEWS IN BRIEF -1-
July 22, 2002
- SSP Aims at 5.7% Sales Rise in Self-Medication Division
July 22, 2002
- BUSINESS NEWS IN BRIEF -2-
July 22, 2002
- MEDICAL DEVICE NEWS IN BRIEF
July 22, 2002
- NEW PRODUCTS
July 22, 2002
- Roche Diagnostics Starts Mouse DNA Chip Consortium
July 22, 2002
- Korosho to Draft Guidelines for Physician-led Clinical Trials
July 22, 2002
- Otsuka Transfers Contract Lab Test Business to BML
July 22, 2002
- Korosho to Set Examples in Reform
July 22, 2002
- GL for Treatment of Esophageal Cancer Prepared
July 22, 2002
- REGULATORY NEWS IN BRIEF
July 22, 2002
- Shortage of Pharmacists Unlikely: Korosho Survey
July 22, 2002
- Aiming to Become Agile, Nimble Innovative Drug Firm: Mr Kannan of Allergan
July 22, 2002
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
July 22, 2002
- Kyowa Hakko Pharma Business to Focus on Cancer, Allergy
July 22, 2002
- 11 of 15 Major Firms Introduce Researchers Rewarding Programs: Survey
July 22, 2002
- Nippon Kayaku Licensed Paclitaxel DDS from NanoCarrier
July 22, 2002
- Korosho Panel Recommends GLs for Infertility Therapy
July 22, 2002
- Fujisawa Licenses Cefzon to Xian-Janssen in China
July 22, 2002
- GL to Include MNZ in Secondary H. pylori Eradication Therapy
July 22, 2002
ページ
Earlier this month, the Ministry of Finance (MOF) unveiled a long list of social security proposals towards the FY2025 budgeting,…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…